| Literature DB >> 35692222 |
Julianne Coelho Silva1, Edson Luiz Cetira Filho1, Paulo Goberlânio de Barros Silva2, Fábio Wildson Gurgel Costa1, Vicente de Paulo Aragão Saboia1.
Abstract
Objectives: The aim of this investigation was to evaluate the effectiveness of collagen cross-linking agents (CCLAs) used in combination with the adhesive technique in restorative procedures. Materials andEntities:
Keywords: Adhesive; Collagen; Cross-linking agents; Dentin; Dentin-bonding agents
Year: 2022 PMID: 35692222 PMCID: PMC9160760 DOI: 10.5395/rde.2022.47.e23
Source DB: PubMed Journal: Restor Dent Endod ISSN: 2234-7658
Inclusion and exclusion criteria
| Inclusion criteria | Exclusion criteria |
|---|---|
| • Randomized clinical trials. | • Non-adopted study designs (case reports, meeting abstracts, letters to the editor, book chapters, authors’ personal opinions, clinical observations, and literature reviews). |
| • Potential studies should have included an experimental group ( | • Studies that also performed a technique that may interfere with adhesion, in addition to the use of CCLAs. |
| • Studies with a control group that used an adhesive system differing from the experimental group. | |
| • Studies not written in languages using a Latin (Roman) alphabet. |
CCLA, collagen cross-linking agent.
Figure 1Flow diagram of the study identification, screening, and inclusion process. Adapted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). References for the 9 excluded articles are listed in Supplementary References.
Main data of selected articles
| Reference | Follow-up | No. of subjects | Placement technique | Type of adhesive + adhesive brand + composite resin brand | No. of restorations per group | CCLAs | Method of application | Criteria | Results |
|---|---|---|---|---|---|---|---|---|---|
| de Souza | Baseline, 6 and 24 mon | 45 | Incremental | ER - ExciTE F (Ivoclar Vivadent AG, Schaan, Liechtenstein) | 45 | PACs (Vitis vinifera, Meganatural Gold, Madera, CA, USA) | Incorporated | RT | The CT showed a significantly higher RT rate after 24 mon than the groups with PAC |
| IPS Empress Direct (Ivoclar Vivadent AG) | PS | After 24 mon no restorations showed PS | |||||||
| MA | Significantly worse marginal adaptation was observed within all groups after 24 mon, without a significant difference detected between any pairs of groups | ||||||||
| RC | No restorations showed recurrent caries lesions after 24 mon | ||||||||
| de Souza | Baseline, 6 and 24 mon | 45 | Incremental | ER - ExciTE F | 45 | PACs (Vitis vinifera, Meganatural Gold, Madera) | Pretreatment | RT | After 24 mon, the group with the highest concentration of PAC showed a significant difference when compared with their respective baseline findings and when compared to the other groups |
| IPS Empress Direct | PS | After 24 mon, no restorations showed PS | |||||||
| MS | A significant difference between baseline vs. 24 mon was observed for all groups, although no significant differences were observed among groups after 24 mon | ||||||||
| MA | Significantly worse MA was observed within all groups after 24 mon, although none of the restorations was considered to have clinically relevant discrepancies | ||||||||
| RC | No restorations showed recurrent caries lesions after 24 mon | ||||||||
| Costa | Baseline, 6,12, 18, and 24 mon | 33 | Incremental | ER or SE - Single Bond Universal 3M ESPE, 3M ESPE, St. Paul, MN, USA) | 39 | 0.1% EGCG (Sigma-Aldrich, St. Louis, MO, USA) for 60 sec | Pretreatment | RT | The results of RT showed no statistically significant difference between any pairs of groups after 24 mon, and for each group when the baseline and 24 mon results were compared |
| Filtek Z350 XT 3M ESPE (3M ESPE) | PS | After 24 mon no restorations showed PS | |||||||
| MS | No significant difference was found between groups at 24 mon and within each group when the baseline and 24 mon findings were compared | ||||||||
| MA | No significant difference was detected between any pair of groups after 24 mon, but a significant difference was detected when the baseline and 24 mon data were compared within the SE control group | ||||||||
| RC | No restorations showed recurrent caries lesion after 24 mon |
CCLA, collagen cross-linking agent; RT, retention; PS, postoperative sensitivity; MS, marginal staining; MA, marginal adaptation; RC, recurrence of caries; CT, control group; PAC, proanthocyanidins; EGCG, epigallocatechin-3-gallate; ER, etch-and-rinse; SE, self-etch.
Figure 2Risk of bias (RoB) summary: review of the authors' assessment of each RoB item, presented as percentages across all included studies in the meta-analysis. Symbol colors: green, low RoB; yellow, unclear RoB; red, high RoB.
Figure 3Forest plot of the retention rates.
CCLA, collagen cross-linking agent; CI, confidence interval.
Figure 4Forest plot of the postoperative sensitivity rates.
CCLA, collagen cross-linking agent; CI, confidence interval.
Figure 5Forest plot of the marginal staining rates.
CCLA, collagen cross-linking agent; CI, confidence interval.
Figure 6Forest plot of the marginal adaptation rates.
EGCG, epigallocatechin-3-gallate; CCLA, collagen cross-linking agent; CI, confidence interval.
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence profile
| Certainty assessment | No. of patients | Effect | Certainty | Importance | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | CCLAs | Control | Relative (95% CI) | Absolute (95% CI) | |||
| Retention of restorations | |||||||||||||
| 3 | Randomized trial | Not serious | Not serious | Not serious | Not serious | None | 86/913 (9.4%) | 25/643 (3.9%) | RR 2.06 (1.29–3.27) | 41 more per 1,000 (from 11 more to 88 more) | ⊕⊕⊕⊕ | CRITICAL | |
| HIGH | |||||||||||||
| Postoperative sensitivity | |||||||||||||
| 3 | Randomized trial | Not serious | Not serious | Not serious | Not serious | None | 3/839 (0.4%) | 7/624 (1.1%) | RR 0.48 (0.12–1.92) | 6 fewer per 1.000 (from 10 fewer to 10 more) | ⊕⊕⊕⊕ | CRITICAL | |
| HIGH | |||||||||||||
| Marginal staining | |||||||||||||
| 3 | Randomized trial | Not serious | Not serious | Not serious | Not serious | None | 60/839 (7.2%) | 21/624 (3.4%) | RR 1.75 (1.10–2.78) | 25 more per 1.000 (from 3 more to 60 more) | ⊕⊕⊕⊕ | CRITICAL | |
| HIGH | |||||||||||||
| Marginal adaptation | |||||||||||||
| 3 | Randomized trial | Not serious | Not serious | Not serious | Not serious | None | 32/839 (3.8%) | 22/624 (3.5%) | RR 1.05 (0.61–1.83) | 2 more per 1.000 (from 14 fewer to 29 more) | ⊕⊕⊕⊕ | CRITICAL | |
| HIGH | |||||||||||||
GRADE Working Group grades of evidence - High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect.
CCLA, collagen cross-linking agent; CI, confidence interval; RR, risk ratio.